Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biospecifics Tech Cp (NQ: BSTC )

88.53 USD UNCHANGED
Last Price Updated: 4:21 PM EST, Dec 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Biospecifics Tech Cp

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 331 companies set new 52-week lows. Key Facts: Naspers (OTC: NAPRF) was the largest firm by market cap to set ... 
Tags ARTL TGGI OBMPD
From Benzinga
How The Pieces Add Up: PBSM Targets $31
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BioSpecifics Technologies Corp. Reports Second Quarter 2019 Financial and Operating Results
- 13% year-over-year increase in royalty revenues for XIAFLEX® - 
From PR Newswire
RSI Alert: Biospecifics Technologies Corp. (BSTC) Now Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Biospecifics Technologies Joins Rank Of Stocks With 95-Plus Composite Rating
Biospecifics Technologies saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 94 to 96. 
From Investor's Business Daily
BioSpecifics Technologies Corp. Announces Authorization of up to $4 Million Stock Repurchase Program
BioSpecifics Technologies Corp. (NASDAQ: BSTC) ("BioSpecifics"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based... 
From PR Newswire
BioSpecifics Technologies Corp. Reports First Quarter 2019 Financial and Operating Results
- 14% year-over-year increase for BioSpecifics first quarter royalty revenues for XIAFLEX - 
From PR Newswire
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2018 Financial Results
- Positive data from Phase 1 trial of CCH for treatment of uterine fibroids presented at 66th Annual Meeting of the Society for Reproductive Investigation in March 2019 - 
From PR Newswire
The Fastest-Growing Health Care Stocks All Have This In Common
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics. 
From Investor's Business Daily
BioSpecifics Technologies Corp. Announces Passing of President Thomas L. Wegman
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed... 
From PR Newswire
The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting ... 
Tags Market News OSIR Top Stories
From Benzinga
Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC... 
From GlobeNewswire News Releases
The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting ... 
Tags FDA KIN AVRO
From Benzinga
Market Trends Toward New Normal in Amarin, BioSpecifics Technologies, Cavco Industries, Iconix Brand Group, A-Mark Precious Metals, and Core-Mark Holding — Emerging Consolidated Expectations, Analyst
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC... 
From GlobeNewswire News Releases
IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses
Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo. 
From Investor's Business Daily
BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development
BioSpecifics Technologies Corp. (NASDAQ: BSTC) a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed... 
From PR Newswire
Managers Of This Fund Like The Outlook For Small-Cap Stocks
This mutual fund is focused on small-cap stocks, and the fund's managers like the outlook for small caps. 
From Investor's Business Daily
BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results
- Positive Phase 3 data from both RELEASE-1 and RELEASE-2 trials of CCH for the treatment of cellulite recently reported - 
From PR Newswire
Biospecifics Tec Up 35.3% Since SmarTrend Uptrend Call (BSTC)
SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on March 12th, 2018 at $42.50. In approximately 8 months, Biospecifics Tec has returned 35.29% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Biospecifics Tec Up 44.8% Since SmarTrend Uptrend Call (BSTC)
SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on March 12th, 2018 at $42.50. In approximately 8 months, Biospecifics Tec has returned 44.85% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids
- Statistically significant reduction in collagen content of CCH treated uterine fibroids - 
From PR Newswire
IBD Stock Of The Day Outperforms Biotech Sector In A Rough October
Emergent BioSolutions is the IBD Stock Of The Day as shares outperform a broad biotech sell-off in October following their third breakout of 2018. 
From Investor's Business Daily
Biospecifics Tec Shares Up 46.0% Since SmarTrend's Buy Recommendation (BSTC)
SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on March 12th, 2018 at $42.50. In approximately 8 months, Biospecifics Tec has returned 46.05% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Investor Expectations to Drive Momentum within Ultrapar Participacoes S.A, BioSpecifics Technologies, GSV Capital, 58, Mitel Networks, and Amarin — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ultrapar Participacoes... 
From GlobeNewswire News Releases
46.4% Return Seen to Date on SmarTrend Biospecifics Tec Call (BSTC)
SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on March 12th, 2018 at $42.50. In approximately 7 months, Biospecifics Tec has returned 46.35% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
36.5% Return Seen to Date on SmarTrend Biospecifics Tec Call (BSTC)
SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on March 12th, 2018 at $42.50. In approximately 7 months, Biospecifics Tec has returned 36.47% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
4 Stocks With Recent Price Strength to Maximize Your Gains
“In the stock game, winning means reaching a higher price.” However, striking the right chord each time needs a fair amount of luck. 
Tags Stocks / Equities
From Blogs - TalkMarkets
38.8% Return Seen to Date on SmarTrend Biospecifics Tec Call (BSTC)
SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on March 12th, 2018 at $42.50. In approximately 7 months, Biospecifics Tec has returned 38.82% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Biospecifics Tec Up 34.1% Since SmarTrend Uptrend Call (BSTC)
SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on March 12th, 2018 at $42.50. In approximately 7 months, Biospecifics Tec has returned 34.12% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
34.3% Return Seen to Date on SmarTrend Biospecifics Tec Call (BSTC)
SmarTrend identified an Uptrend for Biospecifics Tec (NASDAQ:BSTC) on March 12th, 2018 at $42.50. In approximately 6 months, Biospecifics Tec has returned 34.34% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.